Targeted drug shows promise for rare EGFR-Mutant cancers
NCT ID NCT06303167
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 23 times
Summary
This study tests a drug called osimertinib in people with advanced cancers that have specific EGFR gene mutations. The drug blocks a faulty protein that helps cancer grow. Researchers want to see if it can shrink tumors or slow the disease. The trial includes 19 adults with various cancer types, such as lymphoma or solid tumors, that have not responded to other treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ECOG-ACRIN Cancer Research Group
Philadelphia, Pennsylvania, 19103, United States
Conditions
Explore the condition pages connected to this study.